Alliance Global Partners Starts Chromocell Therapeutics Corp. (CHRO) at Buy
Tweet
Share
E-mailGet Alerts CHRO Hot Sheet
Price: $1.35 --0%
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Join SI Premium – FREE
Alliance Global Partners analyst James Molloy initiates coverage on Chromocell Therapeutics Corp. (NYSE: CHRO) with a Buy rating.
For an analyst ratings summary and ratings history on Chromocell Therapeutics Corp. click here. For more ratings news on Chromocell Therapeutics Corp. click here.
Shares of Chromocell Therapeutics Corp. closed at $1.26 yesterday.
You May Also Be Interested In
- UBS Starts Nuvama Wealth Management (NUVAMA:IN) at Buy
- Piper Sandler Starts LightPath Technologies (LPTH) at Overweight
- Benchmark Starts Allegro MicroSystems (ALGM) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
